A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Semaglutide is a powerful aid for managing weight and Type 2 diabetes, but it’s not a free pass to stick with old habits—or skip taking action altogether. If you’ve been struggling with weight loss, ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

The long-term prospects for the company are evolving with product approvals in China, build-up of consumer healthcare franchise, and a biosimilar pipeline.